Eric J. Sherman, MD, highlights several drugs that are being used to treat RET-positive thyroid cancer.
Eric J. Sherman, MD
Advertisement
Articles by Eric J. Sherman, MD
Eric J. Sherman, MD, examines the phase 3 COSMIC-311 trial with cabozantinib in radioiodine-refractory differentiated thyroid cancer.
Eric J. Sherman, MD, highlights trends he observed with immunotherapy in the head and neck cancer space.
Eric J. Sherman, MD, of Memorial Sloan Kettering Cancer Center highlights research on adjuvant capecitabine in nasopharynx cancer.
Advertisement
Latest Updated Articles
Eric J. Sherman, MD, on Agents for Treating RET Fusion–Positive Thyroid CancerPublished: July 17th 2021 | Updated:
- Eric J. Sherman, MD, on Immunotherapy Trends in Head and Neck Cancer
Published: July 10th 2021 | Updated:
- Eric J. Sherman, MD, on the Efficacy of Cabozantinib in Refractory Differentiated Thyroid Cancer
Published: July 16th 2021 | Updated:
- Eric J. Sherman, MD, Discusses the Use of Adjuvant Capecitabine in Nasopharynx Cancer
Published: July 7th 2021 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
2
Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC
3
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
4
Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment
5
